Avego is a multi-strategy healthcare-focused investment firm founded in 2015 with offices in Alpharetta, GA and New York. Through three strategies — Avego Healthcare Capital (private equity), Avego BioScience Capital (venture), and Velan Capital (public equity) — the firm invests across therapeutics, medical products, services, and biotechnology at commercial, mid-to-late stage venture, and public equity stages.
64% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deal in the last 12 months vs 4 prior). Average disclosed round size is $122.7M (across 9 rounds with reported amounts).
Portfolio
9
Fund Size
—
Top Stage
Series A
Last 12 Mo
1
Team
Bala Venkataraman
Founder and Managing Partner
James Flexner
Managing Partner
Thomas Vandervort
Managing Partner
Eric Pham, PhD
Managing Director
Adam Morgan
Partner and CIO of Velan Capital
Kevin McNeill
Partner
Vishal Kapoor
Partner
Morgan Berk
Director of Finance
Christy Kuo, PhD
Principal
Jerry Liao
Principal
Steve Jo
Vice President
Long Yip
Senior Associate
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| TTRexBio, Inc. | Series C | $50M | Jan 2026 |
 MapLight Therapeutics | Series D | $372.5M | Jul 2025 |
 PBS Biotech | Growth | $17M | Jan 2025 |
| AAlentis | Series D | $181.4M | Nov 2024 |
 Evommune | Series C | $115M | Oct 2024 |
 Alentis Therapeutics | Series D | $181.4M | Jan 2024 |
 AtomVie | Series A | $90M | Jun 2023 |
 AtomVie Global Radiopharma | Series A | — | Jun 2023 |
| PBS Biotech | Unknown | $22M | Jan 2023 |
| AtomVie Global Radiopharma | Series A | — | Jan 2023 |
| AAntios Therapeutics, Inc. | Series B | $75M | Nov 2021 |
Top Co-Investors
Last updated: 20 October 2026